NICE guidance supports use of vortioxetine as an option for treating major depressive episodes in adults whose condition has responded inadequately to 2 antidepressants within the current episode. The review notes that NICE acknowledged there was no convincing evidence that vortioxetine was more or less effective than other antidepressants.